Related Experiment Videos
C-fms expression correlates with monocytic differentiation in PML-RAR alpha+ acute promyelocytic leukemia
R Riccioni1, E Saulle, S Militi
1Department of Hematology and Oncology, Istituto Superiore di Sanità, Rome, Italy.
Abstract:
We have investigated the expression of the M-CSF receptor (c-fms) in 16 freshly isolated acute promyelocytic leukemias (APL) expressing the PML/RAR alpha fusion protein. In parallel, we evaluated the capacity of these cells to differentiate along the granulocytic and monocytic pathways. c-fms was constitutively and constantly expressed in all cases sensitive in vivo to all-trans retinoic acid (ATRA) and its expression was further potentiated following in vitro induction with ATRA. Furthermore, gel-shift analysis of APL cells showed elevated levels of PU.1 binding activity to the M-CSF receptor promoter, particularly after ATRA stimulation. Interestingly, the rise of PU.1 binding activity as well as of PU.1 levels after ATRA treatment was significantly higher in APL patients exhibiting monocytic maturation, as compared to those that did not undergo monocytic differentiation. A variable proportion of ATRA-induced APL cells exhibited monocyte-like morphology and immunophenotype: the proportion of monocytic cells was consistently increased by combined treatment with ATRA and diverse hematopoietic growth factors cocktails, which always comprised M-CSF. Monocytic cells originating from in vitro ATRA-induced maturation of APL cells derive from the leukemic clone as suggested by two lines of evidence: (1) monocytic cells harbor the 15;17 translocation; (2) monocytic cells possess Auer bodies. The c-fms(bright) leukemic blasts preferentially showed the capacity for monocytic differentiation as compared to the c-fms(dim/-) subset: indeed, enforced expression of c-fms into NB4, a PML/RAR alpha+ cell line, favored the onset of monocytic maturation. Finally, low c-fms expression was observed in an APL relapsing patient resistant to ATRA, as well as in an APL case with t(11;17), PLZF/RAR alpha+. These observations indicate that PML/RAR alpha+ APL blasts are bipotent for differentiation through both neutrophilic and monocytic lineages, whereby monocytic differentiation is linked to c-fms expression and stimulation.
Insights
Acute promyelocytic leukemia (APL) cells expressing PML/RAR alpha can differentiate into granulocytes or monocytes. Monocytic differentiation is linked to M-CSF receptor (c-fms) expression and stimulation by all-trans retinoic acid (ATRA).
Area of Science:
- Hematology
- Molecular Biology
- Cell Differentiation
Background:
- Acute promyelocytic leukemia (APL) is characterized by the PML/RAR alpha fusion protein.
- APL cells possess the potential for differentiation along multiple myeloid lineages.
- The role of the M-CSF receptor (c-fms) in APL differentiation is not fully understood.
Purpose of the Study:
- To investigate the expression of c-fms in APL cells.
- To evaluate the capacity of APL cells to differentiate into granulocytic and monocytic lineages.
- To determine the relationship between c-fms expression, ATRA treatment, and monocytic differentiation in APL.
Main Methods:
- Analysis of c-fms expression in freshly isolated APL samples.
- In vitro differentiation assays using all-trans retinoic acid (ATRA) and hematopoietic growth factors.
- Gel-shift analysis to assess PU.1 binding activity to the c-fms promoter.
Main Results:
- c-fms was constitutively expressed in ATRA-sensitive APL cases and potentiated by ATRA.
- ATRA stimulation increased PU.1 binding activity to the c-fms promoter, particularly in cases with monocytic maturation.
- Combined ATRA and M-CSF treatment enhanced monocytic differentiation of APL cells, which originated from the leukemic clone.
Conclusions:
- PML/RAR alpha+ APL blasts are bipotent, capable of differentiating into neutrophilic and monocytic lineages.
- Monocytic differentiation in APL is significantly associated with c-fms expression and ATRA stimulation.
- Low c-fms expression may correlate with ATRA resistance and alternative PML/RAR alpha rearrangements.